http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CA-2297900-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_3fcb093a174d5182b5854b704cb09354 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07F9-44 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07F9-38 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07F9-22 |
| filingDate | 1998-07-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b6155e453c3addc346ba046f7d23374f http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c17725718853d7ed4dc5e963ffabaa21 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_28e5ceeac5862b6b5cae7c0d3529b442 |
| publicationDate | 1999-02-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CA-2297900-A1 |
| titleOfInvention | Phosphonic acid naphthylureas and their antiantiogenic and antitumorigenic use |
| abstract | Novel phosphonic acid agents are synthesized and characterized and their pharmaceutical compositions provided. Their method of use for the inhibition of angiogenesis and metalloproteinase and the treatment of tumors is also shown. Embodiments of the phosphonic acid agents include: (P-Yn1)m1-Q1-K-(Q2-(Yn2-P)m2)j wherein P is a phosphonic group or a phosphonic salt, Y is -OCO-, -NR1CO- or CON(R1)R2-; R1 is H, CH2CO2H, or substituted or unsubstituted alkyl; R2 is substituted alkyl, aryl or arylalkyl; Q1 and Q2 are substituted or unsubstituted aryl groups; K is H, -NH-CO-NH-, -NH-CS-NH-, -NHCO-R3-CONH- or -NHCS-R3-CSNH-; provided when K is H, R3 is a substituted or unsubstituted aryl group; j is 0; j is 0,1,2; n1 and n2 are independently 0,1 or 2; and m1 and m2 are independently an integer from 1-4. |
| priorityDate | 1997-07-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 358.